Shanghai Matwings Technology Co., Ltd. (‘Matwings’), a global leader in AI-driven protein design, announced the successful completion of Series A funding rounds, raising tens of millions of USD, led by Qiming Venture Partners.
Matwings is pioneering a new frontier in protein engineering with its proprietary AI-based general protein design platform, AccelProtein™, which directly predicts protein functionality beyond the structural data. By predicting functionality, AccelProtein™ offers a new approach for acquiring high-functioning proteins.
HealthTech Insights: Uwill Founder & CEO Michael London Named Innovator in Healthcare
AccelProtein™ is built on the Pro-PRIME model, a breakthrough developed by a collaborative team led by Professor Liang Hong at Shanghai Jiao Tong University. After years of research focused on data collection, curation, and optimization, the team developed the Pro-series – an AI framework for protein design. Their work, titled “A General Temperature-Guided Language Model to Design Proteins of Enhanced Stability and Activity” was recently published in Science Advances.
A featured case of AccelProtein™’s impact is the design of a specialized Glycosyltransferase enzyme, which is used in the production of EPS-G7, a core material for pancreatitis screening. Within just 4 months, Matwings increased the enzyme’s total glycosylation activity by 7 times, enhanced product specificity from 60% to 98%, and reduced hydrolytic activity by 33%. These improvements cut down the cost of EPS-G7 by 90%.
HealthTech Insights: Meadows Behavioral Healthcare Appoints Marina Rodina as Senior Vice President of Business Development
In another application, Matwings successfully engineered a super alkali-resistant affinity ligand (a nanobody) for affinity chromatography, improving alkali resistance by 3 folds, binding capacity over 100%, and heat stability by 8℃. This innovation saved millions of USD in CMC costs for a Matwings client. Additionally, scale-up production to 5000L has been successfully completed. Such advancement enables low-cost affinity chromatography purification a viable option for a wide range of biologics, bringing more cost-effective solutions for drug production.
HealthTech Insights: Safe Life Enters French Market with Strategic Acquisition of D-Sécurité Groupe
Since 2021, Matwings has successfully delivered over 30 protein-engineering and enzyme-mining projects either proprietary (e.g., Enterokinase, Carboxypeptidase B, KEX2 Protease, Maltogenic Amylase, Subtilisin, Protein A, PETase, T7 RNA Polymerase, and phi29 DNA Polymerase) and co-developed with our stakeholders. These projects span across various applications, including drug innovation, in vitro diagnostics, nutrition and healthcare, food and beverage, and green energy.
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
